Equities

Excelsior Medical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4104:TAI

Excelsior Medical Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (TWD)77.70
  • Today's Change0.10 / 0.13%
  • Shares traded219.23k
  • 1 Year change-5.57%
  • Beta0.1479
Data delayed at least 20 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EXCELSIOR MEDICAL CO., LTD. is a Taiwan-based company principally engaged in the distribution, maintenance and leasing of medical equipment and supplies. The Company’s principal products include artificial kidneys, hemodialysis blood tubing sets and epidural needles, dialysis liquid medicines and powder medicines, dialysis machines, human erythropoietin, surgery consumable materials, blood bags, plasma replacement machines and beauty medical equipment, among others. The Company is also involved in the production and sales of self-owned soybean milk machines, as well as household air fresheners under the brand name of Coway. The Company mainly operates its businesses in domestic market and overseas markets.

  • Revenue in TWD (TTM)8.79bn
  • Net income in TWD804.14m
  • Incorporated1988
  • Employees774.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vizionfocus Inc3.30bn704.51m10.44bn--14.872.809.063.1711.9711.9756.0463.520.53526.415.08--12.3412.9015.1717.3940.6438.0323.0621.992.7930.290.285337.2916.7138.7019.0840.9620.06--
Visco Vision Inc4.07bn759.84m10.93bn--14.412.758.682.6912.0012.0064.2762.920.71283.686.26--13.2911.1917.0814.7243.0539.7618.6417.171.3120.700.191251.6253.1320.06111.0215.049.26--
Taidoc Technology Corp4.34bn1.45bn11.97bn829.008.291.277.342.7615.1315.1345.2798.560.34261.814.24--11.7717.1415.9622.1647.8350.6334.3429.702.26--0.11669.24-3.462.3213.9011.7829.709.23
Excelsior Medical Co Ltd8.79bn804.14m14.64bn774.0016.981.5411.131.674.584.5849.9950.570.43135.175.34--4.875.0410.249.6121.5220.5511.3010.941.41--0.146581.483.715.753.308.4218.345.92
Data as of Feb 11 2026. Currency figures normalised to Excelsior Medical Co Ltd's reporting currency: Taiwan Dollar TWD

Institutional shareholders

2.14%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Feb 20263.36m1.82%
SSgA Funds Management, Inc.as of 05 Feb 2026183.65k0.10%
American Century Investment Management, Inc.as of 05 Feb 2026163.73k0.09%
Dimensional Fund Advisors Ltd.as of 30 Nov 2025156.68k0.09%
DFA Australia Ltd.as of 31 Dec 202551.49k0.03%
FIL Investments Internationalas of 30 Jun 202520.29k0.01%
RAM Active Investments SAas of 30 Jun 20250.000.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.